Health · Full coverage
FDA Approves New Drug Revtorpyk to Significantly Delay Advanced Breast Cancer Progression
How 2 Israeli newsrooms covered this story — translated into English and compared side by side.
50% center
Center 1Right 1
First reported by Ynet · Jul 15, 2026
What happened
The FDA has approved Revtorpyk for advanced HR+/HER2- breast cancer patients resistant to hormonal therapy, significantly delaying disease progression in clinical trials. The drug is used with Fulvestrant, sometimes with Palbociclib, and is currently available only in the U.S.
- 01FDA approves Revtorpyk for advanced HR+/HER2- breast cancer resistant to hormonal therapy.
- 02Revtorpyk combined with Fulvestrant and Palbociclib reduces progression or death risk by 76%.
- 03Median progression-free survival extended to 9.3 months with triple therapy versus 2 months control.
- 04Treatment targets patients without PIK3CA mutations after hormonal and CDK4/6 inhibitor failure.
- 05Side effects include mouth sores, skin reactions, and increased blood sugar; given intravenously weekly.
- 06Currently approved only in the U.S.; further regulatory steps needed for Israel availability.
Summary translated & synthesized from the sources below by baba. Read each original for the full report.
Full coverage · 2 outlets
The same event, reported separately by each newsroom. Open a few to compare what each emphasizes — and what they leave out.
Related stories
FDA Approves Breakthrough Oral Drug for Metastatic Pancreatic Cancer, Offering New Hope4 days agoNew Pancreatic Cancer Drug Approved by FDA Faces Cost and Accessibility Hurdles16 hours agoNew Drug Offers Hope for Polycythemia Vera Patients, Reducing Need for Bloodletting22 minutes agoEli Lilly Expands Early Access to Unapproved Weight Loss Drug Retatrutide Amid Rising DemandAug 4, 2026Cancer Vaccine Shows Promise, Leaving One Patient Disease-Free for More Than Six YearsJun 11, 2026New Targeted Therapies Revolutionize Breast Cancer Treatment and Survival in IsraelJul 5, 2026
